Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Mapatumumab Stories

2011-02-23 00:30:00

SEATTLE, Feb. 23, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that updated phase II study results of OPAXIO (paclitaxel poliglumex) in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% (15/40) of the patients receiving OPAXIO in combination with cisplatin and...

2011-02-16 06:30:00

CALGARY, Feb. 16 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that enrollment has begun in a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus REOLYSIN((R)) versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer. The Principal Investigator is Dr. Tanios Bekaii-Saab, Medical Director of Gastrointestinal Oncology at The Ohio State University...

2011-02-04 06:00:00

ROCKVILLE, Md., Feb. 4, 2011 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), today announced the publication of key papers on the clinical and preclinical development of ENMD-2076, an Aurora A/angiogenic kinase inhibitor. The clinical data were published in the December 3, 2010 on-line issue of the American Association for Cancer Research (AACR) journal, Clinical Cancer Research, and are expected to appear soon in the print version of the publication. Results from the Phase 1...

2011-01-18 06:30:00

CALGARY, Jan. 18 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is part of the National Institutes of Health, has agreed to sponsor a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus REOLYSIN((R)) versus carboplatin and paclitaxel alone in the first line treatment of patients with...

2011-01-11 13:29:00

WALTHAM, Mass., Jan. 11, 2011 /PRNewswire/ -- Syndax, a clinical-stage epigenetics oncology company, announced publication of data of entinostat combined with the demethylating agent Vidaza® (azacitidine) showing effect in reducing tumor burden in differentiated tumor cells in animal tumor models of non-small cell lung cancer (NSCLC). The data is being published in the January 15, 2011 issue of Cancer Research. "These findings demonstrate the promise for epigenetic...

2010-11-04 13:58:05

Phase I trial establishes dose, catalogues side effects, hints at targeted drug's potential An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38 percent of patients with relapsed or therapy-resistant Hodgkin lymphoma enrolled in a phase I clinical trial, investigators report in the Nov. 4 issue of the New England Journal of Medicine. "That level of objective responses to a drug is impressive for a Phase I trial," said study lead author Anas Younes, M.D.,...

2010-10-28 13:55:28

Early-stage trial shows promise against tumors driven by ALK gene alteration A clinical trial of a potential new targeted treatment drug has provided powerful evidence that it can halt or reverse the growth of lung tumors characterized by a specific genetic abnormality. In their report in the October 28 New England Journal of Medicine, a multi-institutional research team reports that daily doses of the investigational drug crizotinib shrank the tumors of more than half of a group patients...

2010-10-27 16:01:00

NEW YORK, Oct. 27 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today the publication of data showing that 57 percent of ALK-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib (PF-02341066), an investigational oral anaplastic lymphoma kinase (ALK) inhibitor, had either a complete (one patient) or partial (46 patients) response to treatment. Data from 82 patients in this Part 2 expansion cohort of the Phase 1 study were published in the...

2010-10-11 14:04:33

Data presented today at the 35th European Society for Medical Oncology Congress Novocure reported today that patients with advanced non-small cell lung cancer (NSCLC) achieved a significant increase in survival time when tumor treating fields (TTF) therapy was added to chemotherapy, as compared to previously reported outcomes for patients receiving chemotherapy alone. Dr. Miklos Pless, head of medical oncology at the Winterthur Hospital Cancer center in Switzerland, presented the data at the...

2010-10-01 14:19:04

Contemporary, diverse population reports rate of chemotherapy administration more than twice that reported by SEER For the first time to date, research published in the October edition of the Journal of Thoracic Oncology (JTO) sought to determine the use of chemotherapy in a contemporary, diverse non-small cell lung cancer (NSCLC) population encompassing all patient ages. Prior population-based studies have shown that only 20 to 30 percent of advanced lung cancer patients receive chemotherapy...